Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Scribe Therapeutics (Nasdaq: SCTX) will participate in healthcare investor conferences beginning November 10, 2026, with CEO Benjamin Oakes scheduled to speak.

Rhea-AI Summary

Scribe Therapeutics (Nasdaq: SCTX) will participate in healthcare investor conferences beginning November 10, 2026, with CEO Benjamin Oakes scheduled to speak. Oakes will join a fireside chat at Guggenheim’s conference in Boston on November 10 at 1:00 PM ET and present at Stifel’s conference in New York on November 11 at 3:20 PM ET. Management will also hold in-person investor meetings during London Life Sciences Week, November 15–20, 2026.

Key Terms

in vivo, crispr

2 terms

in vivo medical

"engineering purpose-built in vivo CRISPR technologies"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

crispr technical

"purpose-built in vivo CRISPR technologies"

CRISPR is a gene‑editing technology that works like precise molecular scissors to change DNA in living cells. For investors, it matters because it can speed development of new therapies, lower research costs, and create valuable intellectual property, but it also carries scientific, regulatory, ethical, and commercial risks that can strongly affect the value and prospects of companies working with the technology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference
Boston, MA
Nov. 10, 2026 at 1:00 PM ET
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer, will participate in a fireside chat.

Stifel Healthcare Conference
New York, NY
Nov. 11, 2026 at 3:20 PM ET
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer, will deliver a presentation.

Management will also host one-on-one meetings with investors in person during London Life Sciences Week taking place Nov. 15-20, 2026.

About Scribe Therapeutics Inc.

Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.

Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com

Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com